mesyl salvinorin B: a kappa-opioid receptor agonist; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 11271318 |
| CHEMBL ID | 365216 |
| SCHEMBL ID | 3541055 |
| MeSH ID | M000609551 |
| Synonym |
|---|
| CHEMBL365216 , |
| (2s,4ar,6ar,7r,9s,10as,10br)-methyl 2-(furan-3-yl)-6a,10b-dimethyl-9-(methylsulfonyloxy)-4,10-dioxo-dodecahydro-1h-benzo[f]isochromene-7-carboxylate |
| (3s,4ar,4bs,6s,8r,8ar,10ar)-3-furan-3-yl-6-methanesulfonyloxy-4a,8a-dimethyl-1,5-dioxo-dodecahydro-2-oxa-phenanthrene-8-carboxylic acid methyl ester |
| bdbm50170676 |
| SCHEMBL3541055 |
| (2s,4ar,6ar,7r,9s,10as,10br)-9-(methanesulfonyloxy)-2-(3-furanyl)-dodecahydro-6a,10b-dimethyl-4,10-dioxo-2h-naphtho[2,1-c]pyran-7-carboxylic acid methyl ester |
| JPQCLBRBPPZECE-VOVNARLJSA-N |
| 862073-79-8 |
| (2s,4ar,6ar,7r,9s,10as,10br)-2-(3-furanyl)dodecahydro-6a,10b-dimethyl-9-[(methylsulfonyl)oxy]-4,10-dioxo-2h-naphtho[2,1-c]pyran-7-carboxylicacid,methylester |
| mesyl salvinorin b |
| methyl (2s,4ar,6ar,7r,9s,10as,10br)-2-(3-furanyl)dodecahydro-6a,10b-dimethyl-9-[(methylsulfonyl)oxy]-4,10-dioxo-2h-naphtho[2,1-c]pyran-7-carboxylate |
| methyl (2s,4ar,6ar,7r,9s,10as,10br)-2-(furan-3-yl)-6a,10b-dimethyl-9-methylsulfonyloxy-4,10-dioxo-2,4a,5,6,7,8,9,10a-octahydro-1h-benzo[f]isochromene-7-carboxylate |
| HY-126910 |
| CS-0108227 |
| AKOS040746102 |
Mesyl Salvinorin B (MSB) is a potent and selective kappa opioid receptor (KOP-r) full agonist. It has potential for development as an anti-psychostimulant agent.
| Excerpt | Reference |
|---|---|
| "Mesyl Salvinorin B (MSB) is a potent and selective kappa opioid receptor (KOP-r) full agonist, with fewer side effects (e.g., sedation or anhedonia) than classic KOP-r full agonists and a longer duration of action in mice than the structurally similar salvinorin A." | ( Effects of mesyl salvinorin B alone and in combination with naltrexone on alcohol deprivation effect in male and female mice. Crowley, R; Kreek, MJ; Prisinzano, T; Zhou, Y, 2018) |
| "Mesyl Salvinorin B (MSB) is a potent selective kappa opioid receptor (KOP-r) agonist that has potential for development as an anti-psychostimulant agent with fewer side-effects (e.g., sedation, depression and dysphoria) than classic KOP-r agonists. " | ( Synergistic blockade of alcohol escalation drinking in mice by a combination of novel kappa opioid receptor agonist Mesyl Salvinorin B and naltrexone. Ben, K; Crowley, RS; Kreek, MJ; Prisinzano, TE; Zhou, Y, 2017) |
| Excerpt | Reference |
|---|---|
| "3-3 mg/kg) or in combination with naltrexone (mu-opioid receptor antagonist at 1 mg/kg) altered alcohol "relapse" drinking using a mouse ADE paradigm." | ( Effects of mesyl salvinorin B alone and in combination with naltrexone on alcohol deprivation effect in male and female mice. Crowley, R; Kreek, MJ; Prisinzano, T; Zhou, Y, 2018) |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Mu-type opioid receptor | Homo sapiens (human) | Ki | 6.8200 | 0.0000 | 0.4197 | 10.0000 | AID238663; AID377275 |
| Delta-type opioid receptor | Homo sapiens (human) | Ki | 10.0000 | 0.0000 | 0.5978 | 9.9300 | AID238721; AID377276 |
| Kappa-type opioid receptor | Homo sapiens (human) | Ki | 0.0023 | 0.0000 | 0.3624 | 10.0000 | AID238722; AID377277 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Kappa-type opioid receptor | Homo sapiens (human) | EC50 (µMol) | 0.0300 | 0.0000 | 0.2244 | 8.9900 | AID240142 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID240468 | Stimulatory effect on [35S]-GTP gammaS binding to Opioid receptor mu1 expressed in CHO cells compared to 10 uM DAMGO; ND = Not determined | 2005 | Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15 | Neoclerodane diterpenes as a novel scaffold for mu opioid receptor ligands. |
| AID240142 | Stimulation of [35S]GTP-gamma-S, binding to Opioid receptor kappa1 expressed in CHO cells | 2005 | Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15 | Neoclerodane diterpenes as a novel scaffold for mu opioid receptor ligands. |
| AID377279 | Selectivity ratio of Ki for delta opioid receptor to kappa opioid receptor | 2006 | Journal of natural products, Jun, Volume: 69, Issue:6 | Synthesis of salvinorin A analogues as opioid receptor probes. |
| AID377277 | Displacement of [125]OXY from kappa opioid receptor | 2006 | Journal of natural products, Jun, Volume: 69, Issue:6 | Synthesis of salvinorin A analogues as opioid receptor probes. |
| AID238663 | Inhibition of [125I]- IOXY binding to human Opioid receptor mu1 | 2005 | Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15 | Neoclerodane diterpenes as a novel scaffold for mu opioid receptor ligands. |
| AID244153 | Relative affinity for human opioid receptor delta1 and kappa1 | 2005 | Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15 | Neoclerodane diterpenes as a novel scaffold for mu opioid receptor ligands. |
| AID240464 | Stimulatory effect on [35S]GTP gammaS binding to Opioid receptor kappa1 expressed in CHO cells compared to 500 nM U50,488 | 2005 | Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15 | Neoclerodane diterpenes as a novel scaffold for mu opioid receptor ligands. |
| AID377275 | Displacement of [125]OXY from mu opioid receptor | 2006 | Journal of natural products, Jun, Volume: 69, Issue:6 | Synthesis of salvinorin A analogues as opioid receptor probes. |
| AID238722 | Inhibition of [125I]- IOXY binding to human Opioid receptor kappa1 | 2005 | Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15 | Neoclerodane diterpenes as a novel scaffold for mu opioid receptor ligands. |
| AID377276 | Displacement of [125]OXY from delta opioid receptor | 2006 | Journal of natural products, Jun, Volume: 69, Issue:6 | Synthesis of salvinorin A analogues as opioid receptor probes. |
| AID240469 | Stimulatory effect on [35S]GTP gammaS binding to Opioid receptor delta 1 expressed in CHO cells compared to 500 nM SNC80; ND = Not determined | 2005 | Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15 | Neoclerodane diterpenes as a novel scaffold for mu opioid receptor ligands. |
| AID240231 | Stimulation of [35S]-GTP gammaS binding to Opioid receptor delta 1 expressed in CHO cells; ND = Not determined | 2005 | Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15 | Neoclerodane diterpenes as a novel scaffold for mu opioid receptor ligands. |
| AID240209 | Stimulation of [35S]GTP-gamma-S, binding to Opioid receptor mu1 expressed in CHO cells; ND = Not determined | 2005 | Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15 | Neoclerodane diterpenes as a novel scaffold for mu opioid receptor ligands. |
| AID377278 | Selectivity ratio of Ki for mu opioid receptor to kappa opioid receptor | 2006 | Journal of natural products, Jun, Volume: 69, Issue:6 | Synthesis of salvinorin A analogues as opioid receptor probes. |
| AID238721 | Inhibition of [125I]- IOXY binding to human Opioid receptor delta1 | 2005 | Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15 | Neoclerodane diterpenes as a novel scaffold for mu opioid receptor ligands. |
| AID244145 | Relative affinity for human opioid receptor mu1 and kappa1 | 2005 | Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15 | Neoclerodane diterpenes as a novel scaffold for mu opioid receptor ligands. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||